Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis Patients

Launched by SOHAG UNIVERSITY · Jun 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the relationship between certain substances in the blood—specifically serum uric acid, serum homocysteine levels, and interleukin-17 (IL-17)—in patients with lupus nephritis, a kidney condition caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease, meaning the body's immune system mistakenly attacks its own tissues, and it often affects women of childbearing age. The goal of this study is to find new, non-invasive ways to assess the severity of lupus nephritis, which can vary from mild to severe.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of SLE that meets specific criteria. They should not have other autoimmune diseases or certain medical conditions, like diabetes or cancer, and must be able to provide informed consent. Participants can expect to answer questions about their health and provide blood samples to help researchers understand the connections between these biomarkers and lupus nephritis. This research could lead to better ways to monitor and treat this serious condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ● Aged ≥18 years.
• • SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) classification criteria and matched controls.
• • Patients cooperative and can answer questions.
• • Patients who are able and willing to give written informed consent
• Exclusion Criteria:
• • ● Individuals with other autoimmune diseases.
• • Patients receive any hyperuricemia treatment
• • Pregnancy
• • Malignancy
• • Diabetes.
• • Hypertension.
• • Heart failure.
• • Hepatic diseases.
• • Chronic renal failure other than lupus nephritis.
• • Renal artery stenosis.
• • Renal vein thrombosis.
• • Intrarenal arteriovenous fistula.
• • Obstructive nephropathy.
• • Urinary tract obstruction that could affect RI of intra renal arteries.
• • Uncooperative patients.
• • Patients not able and willing to give written informed consent.